Circular Genomics Presents Data Validating circRNA Blood Biomarkers for Early Alzheimer's Detection
Circular Genomics has presented data at the CTAD 2026 conference demonstrating that its CircPath™ platform, which utilizes circular RNA (circRNA) blood biomarkers, can predict Alzheimer's disease progression with high accuracy. Based on an NIH-funded study of nearly 2,400 participants, the research shows that combining a 34-circRNA signature with existing pTau217 protein markers significantly improves diagnostic and prognostic capabilities compared to current standards. The company's platform offers a dynamic view of brain biology by capturing real-time gene regulation across synaptic, inflammatory, and metabolic pathways. This technology aims to assist biopharmaceutical companies in de-risking clinical trials by enabling better patient stratification and identifying individuals at risk years before cognitive symptoms emerge. The CircPath™ platform is currently available for Research Use Only (RUO).

Topics: Alzheimer's Disease Biomarkers Circular RNA Clinical Trials Neurodegenerative Diseases